Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.

Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.

MedLine Citation:	PMID: 20039429 Owner: NLM Status: MEDLINE
Abstract/OtherAbstract:	OBJECTIVE: To assess the effect of mycophenolate mofetil compared with intravenous pulses of cyclophosphamide on the nonrenal manifestations of lupus nephritis. METHODS: Patients with active lupus nephritis (renal biopsy class III, IV, or V) were recruited for the study (n = 370) and treated with mycophenolate mofetil (target dosage 3 gm/day) or intravenous cyclophosphamide (0.5-1.0 gm/m(2)/month), plus tapered prednisone, for 24 weeks. Nonrenal outcomes were determined using measures of whole body disease activity, including the British Isles Lupus Assessment Group (BILAG) disease activity index, the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and immunologic variables. RESULTS: Both treatments were effective on whole body disease activity in the systems examined, as indicated by changes in the classic BILAG index. With either treatment, remission was induced, notably in the mucocutaneous, musculoskeletal, cardiovascular/respiratory, and vasculitis systems, and flares were rare, as measured by the SELENA-SLEDAI. Levels of complement C3, C4, and CH50 and titers of anti-double-stranded DNA antibodies were normalized after treatment with either mycophenolate mofetil or intravenous cyclophosphamide. CONCLUSION: In addition to the efficacy of both treatments on the renal system, this analysis showed that remission could also be induced in other systems. There was no clear difference in efficacy between mycophenolate mofetil and intravenous cyclophosphamide in ameliorating either the renal or nonrenal manifestations. Mycophenolate mofetil is, therefore, a suitable alternative to cyclophosphamide for the treatment of renal and nonrenal disease manifestations in patients with biopsy-proven lupus nephritis.

Authors:	Ellen M Ginzler; David Wofsy; David Isenberg; Caroline Gordon; Laura Lisk; Mary-Anne Dooley;
Related Documents :	20815919 - A new tool for detection of type i interferon activation in systemic lupus erythematosus. 8467609 - Complement split product c3d as an indicator of disease activity in systemic lupus eryt... 20656619 - Fatigue in systemic lupus erythematosus and rheumatoid arthritis. 9670329 - Clinical usefulness of antibodies to u1snrnp proteins in mixed connective tissue diseas... 6520229 - Oligo-2',5'-adenylate synthetase activity in peripheral blood mononuclear leukocytes in... 18407149 - Prolactin and autoimmune disease. 17323569 - Pathologic findings in reintroduced przewalski's horses (equus caballus przewalskii) in... 16762609 - Benign thyroid disease: what is the role of nuclear medicine? 11370549 - Penile mondor's disease in a 22-year-old man.
Publication Detail:	Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Detail:	Title: Arthritis and rheumatism Volume: 62 ISSN: 0004-3591 ISO Abbreviation: Arthritis Rheum. Publication Date: 2010 Jan
Date Detail:	Created Date: 2010-01-13 Completed Date: 2010-03-11 Revised Date: 2010-10-13
Medline Journal Info:	Nlm Unique ID: 0370605 Medline TA: Arthritis Rheum Country: United States
Other Details:	Languages: eng Pagination: 211-21 Citation Subset: AIM; IM
Affiliation:	State University of New York Downstate Medical Center, Brooklyn, NY, USA.
Data Bank Information
Bank Name/Acc. No.:	ClinicalTrials.gov/NCT00377637
Export Citation:	APA/MLA Format Download EndNote Download BibTex
MeSH Terms
Descriptor/Qualifier:	Adult Anti-Inflammatory Agents, Non-Steroidal / therapeutic use* Antibodies, Antinuclear / blood, drug effects Complement System Proteins / analysis, drug effects Cyclophosphamide / administration & dosage, therapeutic use* Drug Therapy, Combination Female Glucocorticoids / therapeutic use Humans Immunosuppressive Agents / administration & dosage, therapeutic use* Injections, Intravenous Lupus Nephritis / diagnosis, drug therapy, physiopathology Male Mycophenolic Acid / analogs & derivatives, therapeutic use Prednisone / therapeutic use Prospective Studies Remission Induction Severity of Illness Index Treatment Outcome
Chemical
Reg. No./Substance:	0/Anti-Inflammatory Agents, Non-Steroidal; 0/Antibodies, Antinuclear; 0/Glucocorticoids; 0/Immunosuppressive Agents; 128794-94-5/mycophenolate mofetil; 24280-93-1/Mycophenolic Acid; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 9007-36-7/Complement System Proteins
Investigator
Investigator/Affiliation:	Carlos Abud / ; Sharon Adler / ; Graciela Alarcón / ; Elisa Albuquerque / ; Fernando Almeida / ; Alejandro Alvarellos / ; Gerald Appel / ; Hilario Avila / ; Cornelia Blume / ; Ioannis Boletis / ; Alain Bonnardeaux / ; Alan Braun / ; Jill Buyon / ; Ricard Cervera / ; Nan Chen / ; Shunle Chen / ; Gabriel Contreras / ; António Gomes Da Costa / ; Razeen Davids / ; David D'Cruz / ; Enrique De Ramón / ; Atul Deodhar / ; Mary Anne Dooley / ; Andrea Doria / ; Bertrand Dussol / ; Paul Emery / ; Justus Fiechtner / ; Jürgen Floege / ; Hilda Fragoso-Loyo / ; Richard Furie / ; Rozina Ghazalli / ; Cybele Ghossein / ; Gary Gilkeson / ; Ellen Ginzler / ; Caroline Gordon / ; Jennifer Grossman / ; Jieruo Gu / ; Loïc Guillevin / ; Pierre-Yves Hatron / ; Gisela Herrera / ; Falk Hiepe / ; Frederic Houssiau / ; Osvaldo Hübscher / ; Claudia Hura / ; Joshua Kaplan / ; Gianna Kirsztajn / ; Emese Kiss / ; Ghazali Ahmad Kutty / ; Maurice Laville / ; Maria Lazaro / ; Oliver Lenz / ; Leishi Li / ; Liz Lightstone / ; Sam Lim / ; Michel Malaise / ; Susan Manzi / ; Juan Marcos / ; Olivier Meyer / ; Pablo Monge / ; Saraladev Naicker / ; Nathaniel Neal / ; Michael Neuwelt / ; Kathy Nicholls / ; Nancy Olsen / ; Jose Ordi-Ros / ; Barbara Ostrov / ; Manuel Pestana / ; Michelle Petri / ; Gyula Pokorny / ; Jacques Pourrat / ; Jiaqi Qian / ; Jai Radhakrishnan / ; Brad Rovin / ; Jorge Sanchez-Guerrero / ; Julio Sanchez Roman / ; Joseph Shanahan / ; William Shergy / ; Fotini Skopouli / ; Alberto Spindler / ; Christopher Striebich / ; Robert Sundel / ; Charles Swanepoel / ; Si Yen Tan / ; Guillermo Tate / ; Vladimír Tesar / ; Mohamed Tikly / ; Haiyan Wang / ; Rosnawati Yahya / ; Xueqing Yu / ; Fengchun Zhang / ; Diana Zoruba /
Comments/Corrections
Erratum In:	Arthritis Rheum. 2010 Oct;62(10):3005

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document: Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-o...
Next Document: Functional autoantibodies against serpin E2 in rheumatoid arthritis.